Cite
[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach.
MLA
Tanguy, Julie, et al. “[18F]FMISO PET/CT Imaging of Hypoxia as a Non-Invasive Biomarker of Disease Progression and Therapy Efficacy in a Preclinical Model of Pulmonary Fibrosis: Comparison with the [18F]FDG PET/CT Approach.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 48, no. 10, Sept. 2021, pp. 3058–74. EBSCOhost, https://doi.org/10.1007/s00259-021-05209-2.
APA
Tanguy, J., Goirand, F., Bouchard, A., Frenay, J., Moreau, M., Mothes, C., Oudot, A., Helbling, A., Guillemin, M., Bonniaud, P., Cochet, A., Collin, B., & Bellaye, P.-S. (2021). [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach. European Journal of Nuclear Medicine & Molecular Imaging, 48(10), 3058–3074. https://doi.org/10.1007/s00259-021-05209-2
Chicago
Tanguy, Julie, Françoise Goirand, Alexanne Bouchard, Jame Frenay, Mathieu Moreau, Céline Mothes, Alexandra Oudot, et al. 2021. “[18F]FMISO PET/CT Imaging of Hypoxia as a Non-Invasive Biomarker of Disease Progression and Therapy Efficacy in a Preclinical Model of Pulmonary Fibrosis: Comparison with the [18F]FDG PET/CT Approach.” European Journal of Nuclear Medicine & Molecular Imaging 48 (10): 3058–74. doi:10.1007/s00259-021-05209-2.